Scientific Reports

Table 1 Frequency of NS5A RASs before and after treatment in patients with G/P failure.

From: Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Reference	Amino acid, frequency (%)
Reference	Q24		L28		R30		L31		P32		F37		Q54		P58		A92		Y93
Case 1
Before DCVASV	K	99.6	M	99.6	Q	99.6	L	99.9	P	99.8	F	99.6	Q	99.6	P	99.6	T	97	Y	98.9
	Q	0.2	L	0.2	R	0.2					V	0.2	H	0.3			A	2.9	N	0.6
																			H	0.3
Before G/P	K	99.7	M	99.3	Q	39.1	L	72.6	P	99.9	F	98.9	Q	99.9	P	99.8	K	85.5	Y	99.7
			V	0.6	E	60.8	V	27.5			L	1.0					T	8.4
																	E	4.6
																	R	1.0
After G/P failure	K	99.9	M	99.9	E	99.9	L	99.9	P	99.9	F	99.9	Q	99.9	P	99.9	K	99.9	Y	99.9
Case 2
Before G/P	K	99.2	M	99.4	Q	97.5	L	99.9	P	99.9	L	99.9	Q	99.9	P	99.6	T	94.5	Y	99.8
	Q	0.5	V	0.5	E	2.5											K	3.0
	E	0.3
After G/P failure	K	99.9	M	99.9	E	99.8	L	99.9	P	99.9	L	99.9	Q	99.9	P	99.9	K	99.9	Y	99.9

All amino acid frequencies were detected by ultra-deep sequencing.
HCV-Con1 (accession no. AJ238799) or HCV-J (accession no. D90208) were used as references.
DCVASV daclatasvir and asunaprevir, G/P glecaprevir/pibrentasvir, aa amino acid, RAS resistance-associated substitution.

Back to article page

Search

Advanced search

Quick links